Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCA-NAT in rabbit eyes

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Quinteros, Daniela ^a   Vicario De La Torre, Marta ^b   Andrés Guerrero, Vanessa ^b   Palma, Santiago ^a   Allemandi, Daniel ^a   Herrero Vanrell, Rocío ^b   Molina Martínez, Irene T ^b  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; CARBOXYMETHYLCELLULOSE; HYALURONIC ACID; LIPOSOME; MELATONIN DERIVATIVE; POLOXAMER; POLYMER; UNCLASSIFIED DRUG; 5-METHOXYCARBONYLAMINO-N-ACETYLTRYPTAMINE; ADHESIVE AGENT; ANTIHYPERTENSIVE AGENT; MELATONIN; TRYPTAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG INSTILLATION; DRUG RELEASE; DRUG TOLERANCE; ENCAPSULATION; GLAUCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIPID VESICLE; MALE; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PH; RABBIT; TEAR FILM; VISCOSITY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; LACRIMAL FLUID; MEDICINAL CHEMISTRY; PROCEDURES;

ORYCTOLAGUS CUNICULUS;

ADHESIVES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG LIBERATION; HYDROGEN-ION CONCENTRATION; INTRAOCULAR PRESSURE; LIPOSOMES; MALE; MELATONIN; OSMOLAR CONCENTRATION; PARTICLE SIZE; POLYMERS; RABBITS; TEARS; TRYPTAMINES; VISCOSITY;

EID: 84908191425     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110344     Document Type: Article

References (50)

1. Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58: 1131-1135.
2. Schuman JS (2000) Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 22: 167-208.
3. Flanagan JG (1998) Glaucoma update: epidemiology and new approaches to medical management. Ophthalmic Physiol Opt 18: 126-132.
4. Baudouin C (2008) Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 86: 716-726.
5. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29: 312-334.
6. Debbasch C, Pisella PJ, Warnet JM, Rat P, Baudouin C (2001) Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 42: 642-652.
7. Brasnu E, Brignole-Baudouin F, Riancho L, Warnet JM, Baudouin C (2008) Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines. Mol Vis 14: 394-402.
8. Leung EW, Medeiros FA, Weinreb RN (2008) Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 17: 350-355.
9. Moss SE, Klein R, Klein BE (2000) Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 118: 1264-1268.
10. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP, Rosenstein RE (2007) Melatonin in the eye: implications for glaucoma. Exp Eye Res 84: 1021-1030.
11. Wiechmann AF, Wirsig-Wiechmann CR (2001) Multiple cell targets for melatonin action in Xenopus laevis retina: distribution of melatonin receptor immunoreactivity. Vis Neurosci 18: 695-702.
12. Andres-Guerrero V, Alarma-Estrany P, Molina-Martinez IT, Peral A, Herrero-Vanrell R (2009) Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. Exp Eye Res 88: 504-511.
13. Andres-Guerrero V, Herrero-Vanrell R (2008) [Ocular drug absorption by topical route. Role of conjunctiva]. Arch Soc Esp Oftalmol 83: 683-685.
14. Serle JB, Wang RF, Peterson WM, Plourde R, Yerxa BR (2004) Effect of 5- MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma 13: 385-388.
15. Andrés-Guerrero V, Molina-Martínez IT, Peral A, de las Heras B, Pintor J (2011) The Use of Mucoadhesive Polymers to Enhance the Hypotensive Effect of a Melatonin Analogue, 5-MCA-NAT, in Rabbit Eyes. Invest Ophthalmol Vis Sci 52: 1507-1515.
16. Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology 13: 238-252.
17. Law SL, Huang KJ, Chiang CH (2000) Acyclovir-containing liposomes for potential ocular delivery: Corneal penetration and absorption. Journal of Controlled Release 63: 135-140.
18. Vicario-de-la-Torre M, Benitez del Castillo J, Vico E, de las Heras B, Andres V, et al. (2010) Formulation based on liposomes and bioadhesive polymers for dry eye treatment. Tolerance studies. Invest Ophthalmol Vis Sci 51: E- Abstract 6275.
19. Ludwig A (2005) The use of mucoadhesive polymers in ocular drug delivery. Advanced Drug Delivery Reviews 57: 1595-1639.
20. Cao F, Zhang X, Ping Q (2010) New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system. Drug Deliv 17: 500-507.
21. Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13: 238-252.
22. Vicario-de-la-Torre M, Herrero-Vanrell R, Benitez-del-Castillo JM, Molina-Martinez IT (2007) New formulations for dry eye treatment. Arch Soc Esp Oftalmol 82: 395-396.
23. Burstein N (1997) Clinical Ocular Pharmacology. Boston: Butterworth-Heinemann. 21-45.
24. Zhao M, Thuret G, Piselli S, Pipparelli A, Acquart S (2008) Use of poloxamers for deswelling of organ-cultured corneas. Invest Ophthalmol Vis Sci 49: 550-559.
25. Bhatia A, Kumar R, Katare OP (2004) Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharm Sci 7: 252-259.
26. Purslow C, Wolffsohn JS (2005) Ocular surface temperature: a review. Eye Contact Lens 31: 117-123.
27. Enríquez de Salamanca A, Calonge M, García-Vazquez C, Callejo S, Vila A, et al. (2006) Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. 1416-1425.
28. Camras CB, Toris CB, Tamesis RR (1999) Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging 15: 377-388.
29. Andres-Guerrero V, Vicario-de-la-Torre M, Molina-Martinez IT, Benitez-del- Castillo JM, Garcia-Feijoo J, et al. (2011) Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers. Invest Ophthalmol Vis Sci 52: 3548-3556.
30. Kaur IP, Smitha R (2002) Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm 28: 353-369.
31. Ishibashi T, Yokoi N, Kinoshita S (2003) Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 12: 486-490.
32. Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, et al. (2006) The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 113: 1333-1339.
33. Ayaki M, Yaguchi S, Iwasawa A, Koide R (2008) Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clin Experiment Ophthalmol 36: 553-559.
34. Andres-Guerrero V, Vicario-de-la-Torre M, Molina-Martinez IT, Benitez-del- Castillo JM, Garcia-Feijoo J, et al. (2011) Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers. Invest Ophthalmol Vis Sci 52: 3548-3556.
35. Bartlett JD (2012) Ophthalmic Drug Facts: Facts and Comparisons; (Ed.) iH, editor: Lippincott Williams & Wilkins.
36. Burstein N (1997) Clinical Ocular Pharmacology. Boston: Butterworth-Heinemann.
37. Tiffany JM (1991) The viscosity of human tears. Int Ophthalmol 15: 371-376.
38. Tiffany JM (1994) Viscoelastic properties of human tears and polymer solutions. Adv Exp Med Biol 350: 267-270.
39. Chrai SS, Robinson JR (1974) Ocular evaluation of methylcellulose vehicle in albino rabbits. J Pharm Sci 63: 1218-1223.
40. Patton TF, Robinson JR (1975) Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J Pharm Sci 64: 1312-1316.
41. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC (2006) A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 23: 2709-2728.
42. Krause WE, Bellomo EG, Colby RH (2001) Rheology of sodium hyaluronate under physiological conditions. Biomacromolecules 2: 65-69.
43. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, et al. (1998) Ophthalmic drug delivery systems-Recent advances. Progress in Retinal and Eye Research 17: 33-58.
44. Stein PJ, Clack JW (1994) Topical application of a cyclic GMP analog lowers IOP in normal and ocular hypertensive rabbits. Invest Ophthalmol Vis Sci 35: 2765-2768.
45. Martinez-Aguila A, Fonseca B, Bergua A, Pintor J (2013) Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. Eur J Pharmacol 701: 213-217.
46. Lin HH, Ko SM, Hsu LR (1996) The preparation of norfloxacin-loaded liposomes and their in-vitro evaluation in pig's eye. J Pharm Pharmacol 48: 801-805.
47. Moon JW, Song YK, Jee JP, Kim CK, Choung HK, et al. (2006) Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Invest Ophthalmol Vis Sci 47: 3968-3974.
48. Nii T, Ishii F (2005) Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int J Pharm 298: 198-205.
49. Simmons ST, Sherwood MB, Nichols DA, Penne RB, Sery T, et al. (1988) Pharmacokinetics of a 5-fluorouracil liposomal delivery system. Br J Ophthalmol 72: 688-691.
50. Vemuri S, Rhodes CT (1995) Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv Jul; 70: 95-111.